Compugen posts investor presentation on immuno-oncology antibody pipeline, partnerships and cash runway

Reuters2026/08/03 11:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Compugen highlighted cash balance of $125.3 million as of June 30, 2026, with expected runway into 2029.
Ovarian cancer focus centers on COM701, an anti-PVRIG antibody, with MAIA-ovarian interim analysis projected in Q1 2027.
Pipeline update includes GS-0321, an anti-IL-18BP antibody licensed to Gilead, with a Phase 1 solid-tumor trial advancing.
Partnered program rilvegostomig, a PD-1/TIGIT bispecific derived from COM902, sits in 12 Phase 3 trials under AstraZeneca.
Compugen is eligible for up to $195 million in additional rilvegostomig milestones, with tiered royalties up to mid-single digit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief on August 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Compugen posts investor presentation on immuno-oncology antibody pipeline, partnerships and cash runway

You may also like

Crypto prices